Navigation Links
MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Overall Category in Medical, Dental & Related Services/Trade
Date:5/3/2012

LOS ANGELES, May 3, 2012 /PRNewswire/ -- MD+DI (Medical Device and Diagnostic Industry), UBM Canon's leading brand providing the medical device industry with the latest news, information, and in-depth analysis, wins a 2012 Maggie Award for Best Overall Category in the Medical, Dental & Related Services/Trade for their December 2011 issue. MD+DI's May 2011 cover was also a finalist for the Best Cover (Circ under 50,000)/Trade.

(Photo: http://photos.prnewswire.com/prnh/20120503/LA00412)

(Logo: http://photos.prnewswire.com/prnh/20101214/LA16070LOGO)

The Annual Maggie Awards, presented by the Western Publishing Association, presents awards of excellence to deserving individuals and companies whose work is deemed the Best in the West. Marco Aguilera, Lead Art Director for UBM Canon, accepted the award on behalf of the MD+DI team at the live ceremony in Los Angeles, CA, on April 27, 2012.

"This is a special honor for the entire MD+DI team. I would especially like to thank the Art and Production teams, including Lead Art Director Marco Aguilera, as well as champion editors; Maria, Jamie, and Brian," stated Heather Thompson, Editor-in-Chief of MD+DI. "Winning this award allows us to further challenge ourselves in the years to come. Congratulations to all involved."

Other UBM Canon products nominated this year include:'/>"/>

SOURCE UBM Canon
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Cover in the Medical, Dental & Related Services/Trade Category
2. Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response
3. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
4. Forward step in forecasting global warming
5. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
6. Bionovo to Present at Canaccord Adams Global Growth Conference
7. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
8. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
11. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ALTO, Calif. (PRWEB) , ... July 02, 2015 , ... ... to improve an individual’s quality of sleep, launched its Indiegogo campaign on June 23. ... functionality: Luzi's voice command technology makes it effortless to use, while the integration of ...
(Date:7/1/2015)... , July 1, 2015   Decision Resources ... cited advantages of Otezla are its oral administration, ... as reported by surveyed rheumatologists. Otezla was the ... the treatment of active psoriatic arthritis in ... standard of care includes conventional oral treatments including ...
(Date:7/1/2015)... Bermuda , July 1, 2015  Axovant ... company focused on the treatment of dementia, today ... briefing on July 22 at 5:45 p.m. EDT ... the Alzheimer,s Association International Conference 2015 (AAIC). ... remarks: , Dr. Lawrence Friedhoff ...
(Date:7/1/2015)... IN (PRWEB) , ... July 01, 2015 , ... Apex ... 2015 BIO International Convention in Philadelphia, PA. , The presentation took place ... and outlined the plans for the development of APX3330 for the treatment of pancreatic ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
... Global Challenges Require ... ... opportunity today to engage, innovate and deliver sustainable solutions to the growing global marketplace, said ... of the Delhi Sustainable Development Summit 2010 in India. , , , , ...
... , , SAO PAULO , ... has confirmed that ethanol made from sugarcane is a low ... greenhouse gas,(GHG) emissions. As part of today,s announcement finalizing regulations ... designated,sugarcane ethanol as an advanced biofuel that lowers GHG emissions ...
... Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in ... Johanna Bendell , Director, GI Oncology Research, Sarah Cannon ... /PRNewswire-FirstCall/ - Æterna Zentaris Inc. (Nasdaq: AEZS ; ... specialized in oncology and endocrinology, today announced that its ...
Cached Biology Technology:Sustainability Is A Business Imperative 2EPA Reaffirms Sugarcane Biofuel is Advanced Renewable Fuel with 61% Less Emissions than Gasoline 2EPA Reaffirms Sugarcane Biofuel is Advanced Renewable Fuel with 61% Less Emissions than Gasoline 3EPA Reaffirms Sugarcane Biofuel is Advanced Renewable Fuel with 61% Less Emissions than Gasoline 4Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer 2Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer 3Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer 4Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer 5Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer 6
(Date:6/17/2015)... , and HILDEN, Germany , June 17, ... ; Frankfurt Prime Standard: QIA) today launched new Investigator ® ... forensic laboratories in the United States . ... simultaneously analyze multiple key genomic markers (short tandem repeats or ... Quality Sensor to evaluate the quality of DNA in each ...
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... communicated that it will amount to at least 340 MSEK ... to the rapid increase in market growth and orders received ... communicated guidance that revenue for 2015 will exceed 1,500 MSEK ... to approximately 2,200 MSEK. Due to receipt of ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... that shifts the body's fuel consumption from glucose to fat ... team led by scientists at The University of Texas Medical ... Nature. , While their findings could provide new ... signal that emerged from the dark also presents a new ...
... newly identified human bocavirus was found in nearly 5 ... very young children. Researchers from the Centers for ... the International Conference on Emerging Infectious Diseases , "Our ... with pneumonia in Thailand, especially among young children," says ...
... Institute of Allergy and Infectious Diseases (NIAID), part of ... defect in the immune response of people with the ... of developing serious complications following smallpox vaccination. Led by ... Medical and Research Center in Denver, the researchers used ...
Cached Biology News:Darkness unveils vital metabolic fuel switch between sugar and fat 2Darkness unveils vital metabolic fuel switch between sugar and fat 3Bocavirus infection may be associated with pneumonia in Thailand, especially in children 2Defective immune system response to smallpox vaccine detailed in new study 2Defective immune system response to smallpox vaccine detailed in new study 3
... is the most thoroughly characterized enzyme available ... its overall utility and efficacy. , Its ... PCR applications. , It is QC ... AmpliTaq DNA Polymerase is a 94 kDa ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... DNA Polymerase is a versatile and easy-to ... PCR applications. GCpro Taq DNA Polymerase is ... E. coli, containing the DNA polymerase I ... a highly processive 5'-3' DNA polymerase activity. ...
Aspergillus (IgG) Ab EIA Sample Size: 100 l...
Biology Products: